Worldwide: Update On The EU Regulation Of CBD In Foods And Vaping

On 15 April we issued a client Advisory summarising the current regulatory environment in Europe and the US for foods and cosmetics containing cannabidiol (CBD).

The status of such products, however, remains uncertain in several important respects. This note therefore identifies areas where developments or clarification are currently anticipated and addresses the use of CBD in vaping products.

National and International Control Measures

Following consideration by the World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD), on 24 January 2019 the Director General of WHO wrote to the Secretary General of the United Nations recommending that cannabis and cannabis-related substances be rescheduled in the international drug control framework. The reported reason for the recommendation is to facilitate the trade in such compounds for medical and scientific purposes.

The ECDD proposed that preparations considered to be "pure" CBD should not be scheduled within the International Drug Control Conventions by adding a footnote to the entry for "cannabis and cannabis resin" in Schedule I of the Single Convention on Narcotic Drugs (1961) (the Single Convention) to read "Preparations containing predominantly cannabidiol and not more than 0,2 percent of delta-9-tetrahydrocannabidiol are not under international control".

One of the legal implications of this recommendation would be to leave nominally pure CBD preparations (with less than 0.2% tetrahydrocannbidinol (THC)) outside the strict control imposed by the Single Convention on all substances listed in its Schedule 1, such as cannabis, heroin, cocaine and opium. The UN Commission on Narcotic Drugs in Vienna discussed the adoption of this recommendation on 24 June 2019. The background documentation may be accessed via its WHO page.

EU Decision on Foods Containing CBD

In January 2019, the European Commission updated the Novel Food Catalogue to state that extracts of Cannabis sativa L. and derived products containing cannabinoids are considered as novel foods, as a history of consumption has not been demonstrated. As a result, all extracts of hemp and derived products containing cannabinoids (including CBD) are now regarded by the European Commission as novel. This categorisation applies to the extracts themselves and also any products to which they are added as an ingredient (such as hemp seed oil). Synthetically obtained cannabinoids are also considered to be novel.

The Novel Food Catalogue is not legally binding, but is used as a reference by many authorities in the EU for the purposes of the Novel Food Regulation ((EU) 2015/2283). This change to the Novel Food Catalogue may therefore mean that authorities in the Member States refuse to permit supply of foods and food supplements containing cannabinoids, pending formal approval by the European Food Standards Agency (EFSA) under the Novel Food Regulation.

This practical test will come with the outcome of the first application to the EFSA for a CBD food, which was submitted by Cannabis Pharma s.r.o, for a food supplement containing CBD for adults with a daily intake of up to 130mg. A spokeswoman for EFSA announced at the beginning of June that the European Commission is currently examining this request which will then be transferred to EFSA for further technical and scientific assessment. If the application is successful, the European Commission will issue an implementing regulation adding CBD as a food/ingredient to the list of approved novel foods within seven months. That approval will also specify any applicable conditions of use (e.g., maximum daily intake) or labelling requirements. Any product which differs from the approval will require a further application under the Novel Food Regulation.

In the meantime, manufacturers, distributors and consumers in the EU market may find that the sale of CBD containing foods and food supplements is disrupted unless the products may benefit from the transitional provisions of the Novel Foods Regulation. These allow CBD food products that were lawfully on the market before 1 January 2018 to continue on the market provided an application for an authorisation is submitted before 2 January 2020.

CBD in Vaping Products

Vaping or vaporization products, sometimes referred to as "e-cigarettes", use battery power to heat an element to disperse a solution of propylene glycol or glycerine, water, flavouring and sometimes nicotine, resulting in an aerosol that can be inhaled by the user. Vaping does not create smoke and does not rely on combustion.

It is possible to produce vapor with herbal ingredients if the herbs are placed on top of a surface that heats up to the right temperature for vaporization. To vaporize, the herb must be heated enough so that the plant releases its chemicals in the form of vapor, but not hot enough that the plant burns. The perfect temperatures for vaporizing are between 350°F and 450°F to ensure that vapor is produced without ignition.

Whether the process involves combustion and whether nicotine is contained in the relevant products are key factors for the purposes of classification from a legal perspective. The Tobacco Product Directive (2014/40/EU) regulates not only tobacco products but also products based on plants, herbs or fruits which contain no tobacco, "herbal product for smoking". However, these rules apply only to products consumed via a combustion process (i.e., smoking) or which contain nicotine.

It is also common to see the term "e-cigarette" used by different competent authorities to refer to vaping products, however, only products that can be used for the consumption of nicotine-containing vapour via a mouth piece are legally an "electronic cigarette" under the Tobacco Product Directive. The definition of electronic cigarette under the Directive also covers any components of the product, including cartridges, tanks and the device without cartridge or tank.

It follows that e-liquid products that do not contain nicotine when sold (e.g., disposable electronic cigarettes and 0% nicotine e-liquids) are not deemed to fall within the scope of the Tobacco Product Directive, but are regulated under the EU General Product Safety Directive 2001/95/EC and its corresponding national implementing acts, as a consumer product. There has been, so far, no suggestion that vape products including CBD should be classified as foods (the definition of food applies only to substances that are "ingested") subject to the rules on novel foods referenced above, although some official clarification on this point has not yet been provided.

The General Product Safety Directive imposes requirements concerning the safety of products intended for consumer use, however, there are important divergencies among the EU Member States on the practical scope of the Directive. Currently, there is no harmonisation on how EU Member States treat non-nicotine electronic cigarettes with some countries, such as Greece, imposing a general ban and the UK imposing labelling requirements for those e-cigarettes that do not contain nicotine when sold but can be used to contain nicotine.

Some stakeholders advocate that non-nicotine products should meet the same quality standards as equivalent nicotine-containing products (controlled under the Tobacco Products Directive) in terms of production and emissions generated from the device and to prevent distortion of the market1 which emphasizes the need to issue specific regulations to control these products to effectively ensure consumer safety.

CBD Products in the U.S.

In the US, Congress legalized hemp and its derivatives, such as CBD, through The Agriculture Improvement Act of 2018, enacted in December of last year. Although hemp-derived CBD is now legal, CBD derived from marijuana is still prohibited.

Additional restrictions apply at the federal level, depending on how the hemp-derived CBD is used. The US Food and Drug Administration currently takes the position that CBD cannot be used in foods or dietary supplements because it is the active ingredient in an approved drug Epidiolex. The Food Drug and Cosmetic Act sections 201(ff)(3)(B)(i) and (ii) exclude from use in a food or dietary supplement any ingredient that is the subject of clinical drug trials or is an active ingredient in an approved drug, unless the ingredient was used in foods or dietary supplements prior to that time. CBD can, however, be used in cosmetic products, subject to FDA regulations for all cosmetic products, including requirements that the products be safe, not misbranded, and promoted without drug claims. Over the last few months, FDA has requested comments and held a public hearing on use of CBD in food and dietary supplements, suggesting that its position is still evolving and may change.

Hemp and hemp-derived CBD cosmetic products that meet federal standards must still comply with individual state laws in the states in which they are sold. Currently, these laws range from outright prohibitions to no restrictions at all. Some states that permit CBD products are imposing additional regulatory requirements on top of those imposed by the U.S. FDA. These include state-specific testing requirements (to ensure 0% or a low level of THC) and warning labels. States laws are changing rapidly in this area as states seek to catch up with the federal legalization of hemp, with at least 15 states amending their laws in the last few months to allow hemp-derived CBD products to be sold within their states. Bills are pending in other states, which may be enacted before the end of this year.


1. UK Department of Health. Government response to the consultation on the revised Tobacco Products Directive (2014/40/EU) of January 2016.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions